StreetInsider.com News Articles

Helus Pharma (HELP) PT Lowered to $45 at Guggenheim

Fri, 17 Jul 2026 07:05:59 -0400

Guggenheim lowered its price target on Helus Pharma (NASDAQ: HELP) to $45.00 (from $48.00) while maintaining a Buy rating.

Form 6-K CYBIN INC. For: Jun 26

Thu, 16 Jul 2026 15:17:00 -0400

si-local-file:///var/storage/secattach/20260716/26779348.html

Form 6-K CYBIN INC. For: Jun 26

Thu, 16 Jul 2026 15:17:00 -0400

si-local-file:///var/storage/secattach/20260716/26779348.html

Form D CYBIN INC.

Thu, 16 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26775953.html

Form D CYBIN INC.

Thu, 16 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26775953.html

Form D CYBIN INC.

Thu, 16 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26775962.html

Form D CYBIN INC.

Thu, 16 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26775962.html

Helus Pharma (HELP) PT Lowered to $70 at H.C. Wainwright

Thu, 09 Jul 2026 06:51:28 -0400

(Updated - July 9, 2026 6:51 AM EDT)

H.C. Wainwright analyst Patrick R. Trucchio lowered the price target on Helus Pharma (NASDAQ: HELP) to $70.00 (from $95.00) while maintaining a Buy rating.

The analyst commented: "In its F4Q26 results, reported June 29, Helus reaffirmed that the Phase 3 APPROACH top-line readout remains on track. Importantly, the setup into that readout appears increasingly de-risked, in our view, for two reasons: (1) APPROACH has surpassed 88% enrollment, with recruited participants at approximately the same baseline severity as in Phase 2; and (2) the psychedelic 5-HT2A mechanism has now received external, registration-grade validation — following

Helus Pharma (HELP) PT Lowered to $70 at H.C. Wainwright

Thu, 09 Jul 2026 06:51:28 -0400

(Updated - July 9, 2026 6:51 AM EDT)

H.C. Wainwright analyst Patrick R. Trucchio lowered the price target on Helus Pharma (NASDAQ: HELP) to $70.00 (from $95.00) while maintaining a Buy rating.

Helus Pharma (HELP) PT Lowered to $42 at Canaccord

Wed, 01 Jul 2026 06:38:45 -0400

(Updated - July 1, 2026 6:38 AM EDT)

Canaccord lowered its price target on Helus Pharma (NASDAQ: HELP) to $42.00 (from $45.00) while maintaining a Buy rating.

The analyst commented: "HELP's lead asset, HLP003 (deuterated psilocin analog) is in a Phase 3 program for adjunctive treatment of major depressive disorder (MDD). As part of its recent FY2026 (Mar-26) results update, the company announced that its first Phase 3 trial, APPROACH for HLP003 for adjunct MDD is 88% enrolled, and we are encouraged that management continues to expect to report top-line data in C4Q26. Recall the psychedelic therapeutics space is enjoying solid investor

Helus Pharma (HELP) PT Lowered to $42 at Canaccord

Wed, 01 Jul 2026 06:38:45 -0400

(Updated - July 1, 2026 6:38 AM EDT)

Canaccord lowered its price target on Helus Pharma (NASDAQ: HELP) to $42.00 (from $45.00) while maintaining a Buy rating.

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity